LXS196 (Synonyms: LXS196; IDE196) |
Catalog No.GC32811 |
LXS196 (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. LXS196 has the potential for uveal melanoma research.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1874276-76-2
Sample solution is provided at 25 µL, 10mM.
LXS196 is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma[1][2].
Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1].
LXS196 (compound 9) (15, 30, 75, 150 mg/kg, P.O., mice) shows improved efficacy (regression) in a 92.1 GNAQ uveal melanoma xenograft model in a dose-dependently manner[2].|| Animal Model:|Mice implanted with 92.1 GNAQ mutant uveal melanoma cells[2].|Dosage:|15, 30, 75, 150 mg/kg|Administration:|P.O. (bid) for 35 days|Result:|Dose-dependently suppressed the tumor growth.
[1]. Protein Kinase C Inhibitor LXS196 [2]. US20180179181.
Average Rating: 5
(Based on Reviews and 10 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *